Cargando…
Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience
BACKGROUND: The aim of the study was to evaluate the achievement of ‘no evidence of disease activity’ (NEDA) over a 12-month period in a large multicenter population with relapsing remitting multiple sclerosis (RRMS) treated with delayed-release dimethyl fumarate (DMF) and teriflunomide (TRF) using...
Autores principales: | D’Amico, Emanuele, Zanghì, Aurora, Callari, Graziella, Borriello, Giovanna, Gallo, Antonio, Graziano, Giusi, Valentino, Paola, Buccafusca, Maria, Cottone, Salvatore, Salemi, Giuseppe, Ragonese, Paolo, Bossio, Roberto Bruno, Docimo, Renato, Grimaldi, Luigi Maria Edoardo, Pozzilli, Carlo, Tedeschi, Gioacchino, Zappia, Mario, Patti, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131312/ https://www.ncbi.nlm.nih.gov/pubmed/30210582 http://dx.doi.org/10.1177/1756286418796404 |
Ejemplares similares
-
Pregnancy and the Postpartum Period in Women With Relapsing-Remitting Multiple Sclerosis Treated With Old and New Disease-Modifying Treatments: A Real-World Multicenter Experience
por: Zanghì, Aurora, et al.
Publicado: (2020) -
Comparable Efficacy and Safety of Teriflunomide versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis
por: Nehzat, Nasim, et al.
Publicado: (2021) -
Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016) -
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic
por: Zanghì, Aurora, et al.
Publicado: (2022) -
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
por: D’Amico, Emanuele, et al.
Publicado: (2022)